25046-79-1 Usage
Description
Glisoxepide, also known as G410600, is a sulfonylurea derivative that functions as an antidiabetic drug. It is specifically designed for the treatment of diabetes mellitus type 2, helping to regulate blood sugar levels and improve the body's response to insulin.
Uses
Used in Pharmaceutical Industry:
Glisoxepide is used as an antidiabetic drug for the treatment of diabetes mellitus type 2. It aids in managing blood sugar levels by enhancing the secretion of insulin from the pancreas, thus improving the body's response to insulin and promoting better glucose uptake by the cells.
Originator
Pro-Diaban,Bayer,W. Germany,1974
Manufacturing Process
There is obtained from 4-[β-[5-methyl-isoxazolyl-(3)-carboxamido]-ethyl]-
benzene-sulfonamide (prepared from 5-methyl-isoxazole-(3)-carboxylic acid
chloride and 4-(β-aminoethyl)benzene-sulfonamide hydrochloride, MP 213° to
214°C in pyridine) and chloroformic acid methyl ester, in a yield of 69%, the
compound N-[[-4-[β-[5-methyl-isoxazolyl-(3)-carboxamido]-ethyl]]-benzenesulfonyl]]-methyl-urethane in the form of colorless crystals of MP 173°C.
From the sulfonyl-urethane described above and N-amino-hexamethyleneimine, there is obtained, in a yield of 70%. the compound 4-[[4-[β-[5-methylisoxazolyl-(3)-carboxamido]-ethyl]-benzene-sulfonyl]]-1,1-hexamethylenesemicarbazide in the form of colorless crystals of MP 189°C.
Therapeutic Function
Oral hypoglycemic
Check Digit Verification of cas no
The CAS Registry Mumber 25046-79-1 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 2,5,0,4 and 6 respectively; the second part has 2 digits, 7 and 9 respectively.
Calculate Digit Verification of CAS Registry Number 25046-79:
(7*2)+(6*5)+(5*0)+(4*4)+(3*6)+(2*7)+(1*9)=101
101 % 10 = 1
So 25046-79-1 is a valid CAS Registry Number.
InChI:InChI=1/C20H27N5O5S/c1-15-14-18(23-30-15)19(26)21-11-10-16-6-8-17(9-7-16)31(28,29)24-20(27)22-25-12-4-2-3-5-13-25/h6-9,14H,2-5,10-13H2,1H3,(H,21,26)(H2,22,24,27)
25046-79-1Relevant articles and documents
Combinations comprising dipeptidylpeptidase-iv inhibitor
-
, (2008/06/13)
The invention relates to a combination which comprises a DPP-IV inhibitor and at least one further antidiabetic compound, preferably selected from the group consisting of insulin signalling pathway modulators, like inhibitors of protein tyrosine phosphatases (PTPases), non-small molecule mimetic compounds and inhibitors of glutamine-fructose-6-phosphate amidotransferase (GFAT), compounds influencing a dysregulated hepatic glucose production, like inhibitors of glucose-6-phosphatase (G6Pase), inhibitors of fructose-1,6-bisphosphatase (F-1,6-BPase), inhibitors of glycogen phosphorylase (GP), glucagon receptor antagonists and inhibitors of phosphoenolpyruvate carboxykinase (PEPCK), pyruvate dehydrogenase kinase (PDHK) inhibitors, insulin sensitivity enhancers, insulin secretion enhancers, α-glucosidase inhibitors, inhibitors of gastric emptying, insulin, and α2-adrenergic antagonists, for simultaneous, separate or sequential use in the prevention, delay of progression or treatment of conditions mediated by dipeptidylpeptidase-IV (DPP-IV), in particular diabetes, more especially type 2 diabetes mellitus, conditions of impaired glucose tolerance (IGT), conditions of impaired fasting plasma glucose, metabolic acidosis, ketosis, arthritis, obesity and osteoporosis; and the use of such combination for the cosmetic treatment of a mammal in order to effect a cosmetically beneficial loss of body weight.
